CHAMPIONS ONCOLOGY, INC. (CSBR) Form 10-K — Jul 27, 2026
For the fiscal year ended April 30, 2026, Champions Oncology reported revenue of $59.4 million, an increase of 4.4% compared to the prior year. This growth was primarily driven by pharmacology services, which rose to $57.1 million, offsetting a decline in TOS data license revenue and other TOS revenue. Despite the revenue growth, the company's profitability deteriorated, resulting in a net loss of $1.2 million compared to net income of $4.7 million in fiscal 2025. The decrease in profitability was attributed to increased investments in research and development, which rose 33.1% to $9.1 million, along with higher sales and marketing expenses.
Key figures
- Revenue
- 59425000
- Cash Position
- 4872000
- Shares Outstanding
- 13893569
- Research And Development Expense
- 9084000
Price after filing
Close on the filing date to close N calendar days later (from $6.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.